GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Devonian Health Group Inc (OTCPK:DVHGF) » Definitions » Gross Margin %

DVHGF (Devonian Health Group) Gross Margin % : 29.16% (As of Oct. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Devonian Health Group Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Devonian Health Group's Gross Profit for the three months ended in Oct. 2024 was $1.24 Mil. Devonian Health Group's Revenue for the three months ended in Oct. 2024 was $4.25 Mil. Therefore, Devonian Health Group's Gross Margin % for the quarter that ended in Oct. 2024 was 29.16%.


The historical rank and industry rank for Devonian Health Group's Gross Margin % or its related term are showing as below:

DVHGF' s Gross Margin % Range Over the Past 10 Years
Min: -16.34   Med: 24.34   Max: 61.33
Current: 32.06


During the past 11 years, the highest Gross Margin % of Devonian Health Group was 61.33%. The lowest was -16.34%. And the median was 24.34%.

DVHGF's Gross Margin % is ranked worse than
74.6% of 744 companies
in the Biotechnology industry
Industry Median: 60.565 vs DVHGF: 32.06

Devonian Health Group had a gross margin of 29.16% for the quarter that ended in Oct. 2024 => Competition eroding margins

The 5-Year average Growth Rate of Gross Margin for Devonian Health Group was 0.00% per year.


Devonian Health Group Gross Margin % Historical Data

The historical data trend for Devonian Health Group's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Devonian Health Group Gross Margin % Chart

Devonian Health Group Annual Data
Trend Jun15 Jun16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23 Jul24
Gross Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -3.27 -16.31 24.35 38.03 33.62

Devonian Health Group Quarterly Data
Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.52 34.02 24.43 37.70 29.16

Competitive Comparison of Devonian Health Group's Gross Margin %

For the Biotechnology subindustry, Devonian Health Group's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Devonian Health Group's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Devonian Health Group's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Devonian Health Group's Gross Margin % falls into.



Devonian Health Group Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue.

Devonian Health Group's Gross Margin for the fiscal year that ended in Jul. 2024 is calculated as

Gross Margin % (A: Jul. 2024 )=Gross Profit (A: Jul. 2024 ) / Revenue (A: Jul. 2024 )
=4.4 / 12.991
=(Revenue - Cost of Goods Sold) / Revenue
=(12.991 - 8.624) / 12.991
=33.62 %

Devonian Health Group's Gross Margin for the quarter that ended in Oct. 2024 is calculated as


Gross Margin % (Q: Oct. 2024 )=Gross Profit (Q: Oct. 2024 ) / Revenue (Q: Oct. 2024 )
=1.2 / 4.253
=(Revenue - Cost of Goods Sold) / Revenue
=(4.253 - 3.013) / 4.253
=29.16 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Devonian Health Group  (OTCPK:DVHGF) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Devonian Health Group had a gross margin of 29.16% for the quarter that ended in Oct. 2024 => Competition eroding margins


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Devonian Health Group Gross Margin % Related Terms

Thank you for viewing the detailed overview of Devonian Health Group's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Devonian Health Group Business Description

Traded in Other Exchanges
Address
360, Rue des Entrepreneurs, Montmagny, QC, CAN, G5V 4T1
Devonian Health Group Inc is operating in the pharmaceutical sector. It is engaged in the development and distribution of botanical drugs. The group is also involved in the development of value-added products for dermo-cosmetics. It has established a research effort focused on the anticipation of new solutions in the medical sector as well as in the cosmetic sector. The company's technology platform, The Supra Molecular Complex Extraction and Stabilization Technology provides a process of extraction, purification, stabilization, and conditioning of molecular complexes, as active botanical ingredients, from plants and algae. Its product portfolio includes pharmaceuticals like Thykamine, Pantoprazole, and Cleo-35; and cosmeceutical products like R-Spinasome and Purgenesis.

Devonian Health Group Headlines